Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Victoria, Australia.
Australian Institute for Musculoskeletal Science, University of Melbourne and Western Health, St Albans, Victoria, Australia.
BMJ Open. 2019 May 1;9(4):e025145. doi: 10.1136/bmjopen-2018-025145.
Remission rates for mood disorders, including depressive and bipolar disorders, remain relatively low despite available treatments, and many patients fail to respond adequately to these interventions. Evidence suggests that personality disorder may play a role in poor outcomes. Although personality disorders are common in patients with mood disorders, it remains unknown whether personality disorder affects treatment outcomes in mood disorders. We aim to review currently available evidence regarding the role of personality disorder on pharmacological interventions in randomised controlled trials for adults with mood disorders.
A systematic search of Cochrane Central Register of Controlled Clinical Trials (CENTRAL) via cochranelibrary.com, PubMed via PubMed, EMBASE via embase.com, PsycINFO via Ebsco and CINAHL Complete via Ebsco databases will be conducted to identify randomised controlled trials that have investigated pharmacological interventions in participants aged 18 years or older for mood disorders (ie, depressive disorders and bipolar spectrum disorders) and have also included assessment of personality disorder. One reviewer will screen studies against the predetermined eligibility criteria, and a second reviewer will confirm eligible studies. Data will be extracted by two independent reviewers. Methodological quality and risk of bias will be assessed using the Cochrane Risk of Bias tool. A systematic review, and if sufficient evidence is identified, a meta-analysis will be completed. Meta-analysis will be conducted using the standardised mean difference approach and reported with 95% CIs. A random effects model will be employed and statistical heterogeneity will be evaluated using the I statistic. Prespecified subgroup analyses will be completed.
As this systematic review will use published data, ethics permission will not be required. The outcomes of this systematic review will be published in a relevant scientific journal and presented at a research conference.
CRD42018089279.
尽管有可用的治疗方法,但包括抑郁障碍和双相情感障碍在内的心境障碍的缓解率仍然相对较低,许多患者对这些干预措施的反应不够充分。有证据表明,人格障碍可能在不良结局中发挥作用。尽管心境障碍患者中常见人格障碍,但仍不清楚人格障碍是否会影响心境障碍的治疗结局。我们旨在综述目前关于人格障碍对心境障碍成年患者药物干预的随机对照试验中的作用的现有证据。
通过 cochranelibrary.com 对 Cochrane 中央对照临床试验注册库(CENTRAL)、PubMed、embase.com 上的 EMBASE、Ebsco 上的 PsycINFO 和 Ebsco 上的 CINAHL Complete 进行系统检索,以确定对 18 岁或以上的心境障碍(即抑郁障碍和双相谱系障碍)患者进行药物干预的随机对照试验,并且还包括人格障碍评估。一名审查员将根据预定的纳入标准筛选研究,第二名审查员将确认符合条件的研究。数据将由两名独立的审查员提取。使用 Cochrane 偏倚风险工具评估方法学质量和偏倚风险。如果有足够的证据,将进行系统综述和荟萃分析。荟萃分析将使用标准化均数差方法进行,并报告 95%置信区间。将采用随机效应模型,并使用 I 统计量评估统计异质性。将进行预设的亚组分析。
由于本系统评价将使用已发表的数据,因此不需要伦理许可。本系统评价的结果将发表在相关科学期刊上,并在研究会议上报告。
CRD42018089279。